electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review the results and answer questions.
Participants may join by telephone or webcast using the details below.
Wednesday, November 4, 2026 at 4:30 pm EST
Participant Dial-In: 877-407-8835 / +1 201-689-8779
Conference ID #: 13763480
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=af6qsd3k
A replay of the webcast will be available in the Investors section of the Company’s website at investor.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
Media gallery